The effects of vitamin D supplementation in the prevention and treatment of rickets and osteomalacia are well established but its influence on non-bone diseases is far more elusive (1) .
Within respiratory epidemiology, investigators speculate that vitamin D may affect both immune cells and airway smooth muscle which may have a direct effect on lung function, and indeed some studies have found that low vitamin D status may be associated with impaired lung function, airway hyperresponsiveness and other markers of asthma severity (2) (3) (4) (5) . While most studies have been conducted in the general population (2, 3, (6) (7) (8) (9) , fewer studies have investigated the association between vitamin D status and lung function in adults with asthma (4, (10) (11) (12) (13) (14) .
In adults with asthma, mixed results have been observed in cross-sectional studies (4, (11) (12) (13) (14) and one most recent randomized trial did not find an association between vitamin D supplementation for 28 weeks and change in lung function (10) . Given the inconsistencies between these studies, further studies are needed, particularly using a prospective cohort or interventional design with follow-up for several years.
Studies in the general population have observed that the association between low vitamin D status and lung function decline may differ by smoking status (3, 8, 9, 15) , with the hypothesized association being stronger in smokers. However, in adults with asthma, only one cross-sectional study has investigated this issue, and the association did not vary by smoking status (11) . Another subgroup of interest is people with asthma who are not treated with inhaled corticosteroids (ICS); they also may be more responsive to the putative beneficial effects of vitamin D (4).
In a previous cross-sectional study conducted in the Nord-Trøndelag Health Study (HUNT), Larose et al. investigated the association of vitamin D status and lung function in 760 adults with asthma (12) . We now have the opportunity to investigate the association between vitamin D status and lung function decline after an average 11 years of follow-up. We analyzed these unique data from the HUNT Study to investigate 1) the association between vitamin D status and lung function decline in adults with asthma; and 2) whether this association was modified by smoking status or ICS use.
METHODS

Study population
The HUNT Study is a population based study comprised of three surveys conducted in 1984-86 (HUNT1), 1995-97(HUNT2) and 2006-08(HUNT3) in the county of Nord-Trøndelag, Norway.
Adults aged 20 years or older in the population of Nord-Trøndelag (n=93,898 in 1997) were invited to participate in each of the surveys (16) . Our study utilized those participating in HUNT2 (n=65,237) and HUNT3 (n=50,807) as information on asthma was not collected in HUNT1 (n=77,212) (16) . Of the survey participants, 37,071 participated in both HUNT2 and HUNT3, of which 548 reported asthma and were under the age of 55 in HUNT2. For the present analysis, we will refer to HUNT2 as "baseline" and HUNT3 as "follow-up". Asthma was defined as those answering "yes" to three questions -1) "Do you have or have you had asthma?" at baseline, 2) "Have you had attacks of wheezing or breathlessness during the last 12 months?" at baseline, and 3) "Do you have or have you had asthma?" at follow-up -and "no" to a fourth question: "Have you had or do you have any of the following: chronic bronchitis, emphysema or chronic obstructive pulmonary disease " at follow-up. Additionally, to exclude others with chronic obstructive pulmonary disease, participants with a forced expiratory volume in 1 second (FEV 1 ) / forced vital capacity (FVC) ratio <70% at baseline were excluded. A further 153 participants were excluded because they did not have measurements of vitamin D status at baseline or lung function measures either at baseline or at follow-up, leaving 395 participants in our analysis cohort. In the subgroup analyses by smoking status (n=387), an additional 8 participants were excluded because of missing information on smoking status. All 395 subjects had information on ICS use. Current smokers responded "yes" to "Do you smoke -cigarettes daily?". Former smokers respond "no" to "Do you smoke -cigarettes daily?" but did not indicate that they never smoked daily. Never smokers respond "no" to "Do you smoke -cigarettes daily?" and "yes" to "Never smoked daily". Table 3 presents the primary analyses stratified by smoking status. Among never smokers, having serum 25(OH)D <50 nmol/L was associated with more decline in FEV 1 and FVC compared to having serum 25(OH)D ≥50 nmol/L (adjusted mean decline 445 ml vs. 222 ml, and 347 ml vs. 128 ml, respectively) (p-values=0.01 and 0.01, respectively). In never smokers, we also observed more decline in the FEV 1 /FVC ratio in those with serum 25(OH)D <50 nmol/L than ≥50 nmol/L with an adjusted mean decline of 4.2 vs. 2.8%, respectively (p-value=0.12). By contrast, no clear associations were observed in ever smokers. The p-value for interaction between serum 25(OH)D, and smoking status was 0.08 for decline in FEV 1 and 0.14 for decline in FVC. 
DISCUSSION
In this prospective cohort study, we observed a weak association between low serum 25(OH)D levels and more lung function decline in adults with asthma, although this apparent difference was not statistically significant. The association was stronger among never smokers and non-ICS users, and null in their counterparts (i.e., ever smokers and ICS users). These subgroup findings suggest that the association between high serum 25(OH)D levels and lung function may be more complex than previously appreciated.
The mean rates of lung function decline in our study were comparable to other previously reported rates of decline in adults with asthma (23, 24) . For example, in a 15-year follow-up study of 1,095 adults with asthma, Lange et al. found the mean decline in FEV 1 was 38 ml per year (23) . Additionally, in a study which included 713 adults with asthma, similar rates of decline were observed for both FEV 1 and FVC (24) . Rates of lung function decline are generally higher in smokers, and the slight differences in these rates and our rates (38 vs. 31ml) may be attributed to differences in such a characteristic (25% current smokers in our study versus 68-74% current smokers in the study by Lange et al.) .
To the best of our knowledge, we present the first analysis of the association between serum 25(OH)D and lung function decline over a long time period in adults with asthma. For study design reasons alone, the current data go well beyond several cross-sectional studies on the association between vitamin D status and lung function in adults with asthma. Four of these cross-sectional studies found that serum 25(OH)D levels were associated with impaired lung function (4, 11, 13, 14) and one did not find a clear association (12) . These studies generally only adjusted for a limited number of confounders (such as age, sex and body mass index) and the temporality of the association could not be assessed. In contrast, the current study adjusted for many additional potential confounding factors, including physical activity, smoking status, socio- influence on lung function, one might expect to capture the association only by studying such a long time period. While we only observed a weak association between serum 25(OH)D and lung function decline in the total cohort, we did observe stronger associations in never smokers and non-ICS users. In the general population, several prospective studies have found a stronger association in smokers compared to non-smokers (3, 8, 9, 15) . In adults with asthma, only one other study has investigated this subgroup (11) . This cross-sectional study, which included 435
Chinese adults, did not find that the 25(OH)D-lung function association differed between smokers and non-smokers (11) . In contrast to previous studies, we found, in Norwegian adults (25) . Vitamin D may influence airway remodeling by affecting airway smooth muscle growth and contractility, fibroblast proliferation, extracelluar matrix proteins and matrix metalloproteinase production (25) . In a murine model of airways in chronic asthma, vitamin D treatment with ovalbumin challenge reduced inflammation and structural changes (26) . In asthma, extensive airway remodeling can occur including abnormally thickened epithelium with mucus gland hypertrophy, altered fibrosis composition, and greatly increased airway smooth muscle mass and this might have a direct effect on lung function (25) .
For example, in people with asthma, thickening of the basement membrane has been negatively associated with FEV 1 (27) .
A strength of the current study is that serum 25(OH)D was measured at baseline and we were able to analyze lung function decline after the time of blood sampling. This longitudinal design may provide us with an insight in to the temporality of the association between serum 25(OH)D and lung function decline that cannot be observed in cross-sectional studies. Our study also included a reasonably large number of participants and serum 25(OH)D, lung function and anthropometric data were measured by trained health professionals. Additionally, we had information on the participants' health and lifestyle which allowed us to control for a range of potential confounders.
Despite such strengths, our study had several limitations. Because of the longitudinal design, it is possible that selection bias may have occurred as entry into our study required that participants were able to attend the follow-up. However, in a study of non-responders to the HUNT Study, generally participants did not report differently from non-participants in terms of unhealthy lifestyle factors (i.e. body mass index and smoking status) or asthma status, which argues against major selection bias in the current study (28) . Additionally, participants in our analysis required complete data on serum 25(OH)D and lung function. However, when we compared our analysis cohort to those with missing data no substantial differences were found (Web Table 1 ).
Additionally, our study excluded participants with chronic obstructive pulmonary disease using pre-bronchodilator measurements, and some of the most severe asthma cases may have been excluded. This may have influenced our results, however, when we included those who met this criteria but did not have a history of smoking, the results were similar to the total cohort (adjusted a Adjusted age, sex, height, body mass index, smoking status (never, current, former, unknown), education (<10years, ≥10 years, unknown), physical activity (<1hr week, ≥1hr week, unknown), socioeconomic status (high, low, unknown), use of asthma medication ever (yes, no), use of inhaled corticosteroids ever (yes, no), season of blood sample (winter, spring, summer, autumn). 
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